Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Routine EEGs may hold hidden clues to childhood epilepsy — a new analysis method is put to the test

NCT ID NCT06546410

Diagnosis Sponsor: Neuronostics Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study is testing whether a computer tool called BioEP can detect signs of seizure susceptibility in standard EEG recordings from children with epilepsy. Researchers will analyze past EEGs from 530 children aged 2 to 18 who already have an epilepsy diagnosis. The goal is to see if BioEP can reliably distinguish children with epilepsy from those without, which could lead to faster and more efficient diagnosis in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BioEP — a computer analysis applied to routine EEG recordings
What this could lead to
If validated, BioEP could help doctors diagnose epilepsy faster and with fewer appointments, reducing stress and cost for families.
What could go wrong
This is a retrospective study using existing data, so it can suggest but not prove that BioEP works in real time. The results may not apply to all types of epilepsy or to children outside the study's age range.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

530 people

The number who actually took part.

Started

Jan 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Paediatric population with a diagnosis of epilepsy.

Ages

2 to 18 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥2-\<18 years age. * Patients who have had a confirmed epilepsy diagnosis for ≥1+ year. * Non contributary first EEG: including routine EEG, sleep EEG (natural, melatonin induced, sleep deprived), 24-hour ambulatory EEG. * Patients who have been diagnosed with a self-limited and or focal epilepsy \[\*\] who have had a first non-contributary (no IEDS present, negative) outpatient EEG. * Patients who have been diagnosed with idiopathic generalised epilepsy \[†\] who have had a first non-contributary (no IEDS present, negative) routine EEG. * Neurodiverse patients with epilepsy can be included in the study \[‡\] * Patients with epilepsy and co-morbidities can be included in the study (anxiety, mood disorders etc) * Controls should be EEGs taken from patients who have been referred for a paroxysmal disorder, received an EEG as part of their diagnostic work up and subsequently received an alternate diagnosis. Epilepsy should have been excluded from their differential diagnosis and the alternate diagnosis should have remained stable for ≥1+ year. Exclusion Criteria: * Developmental and/or epileptic encephalopathies \[§\] * Patients with global development delay of unknown origin. * Patients with profound and multiple intellectual disabilities * Participants with a known hepatic/renal encephalopathy. * Patient diagnosed with possible NEAD and epilepsy (dual diagnosis). * Participants taking part in another Clinical Trial of an Investigational Medicinal Product (CTIMP) (qualitative/observational studies are acceptable). * Patients with any breaches of skull (plates, burr holes, shrapnel).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

childhood-onset epilepsy syndrome epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epilepsy Epilepsy in children

Contacts and locations

Locations

  • Alder Hey Children's NHS Foundation Trust

    Liverpool, United Kingdom

  • Great Ormond Street Hospital for Children

    London, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

  • Maidstone & Tunbridge Wells NHS Trust

    Maidstone, United Kingdom

  • Manchester University NHS Foundation Trust

    Manchester, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton, SO166YD, United Kingdom

  • Worcestershire Acute Hospital NHS Trust

    Worcester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.